- $136.04m
- $29.19m
- $33.03m
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026
Brief: MaxCyte Q3 Gross Profit USD 5.2 Million
Gene therapy firm MaxCyte misses Q3 revenue estimates
Brief: MaxCyte Q3 Revenue USD 6.4 Million Vs. IBES Estimate USD 8.37 Million
Brief: Maxcyte Announces Operational Restructuring To Reduce Costs
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: MaxCyte Q2 Revenue USD 8.2 Million Vs. IBES Estimate USD 9.53 Million
MaxCyte Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Maxcyte Signs Platform License Agreement With Adicet Bio
Brief: MaxCyte Announces Strategic Platform Licensing Agreement With Anocca AB To Advance Tcr-T Cell Therapy Pipeline
Brief: MaxCyte Says Nasdaq Listing Unaffected By AIM Delisting - SEC Filing
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
RCS - MaxCyte, Inc. - MaxCyte and Ori Biotech Announce Collaboration
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company